Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Ramesh Kumar Biography and Net Worth

Director of Ocugen

Dr. Ramesh Kumar Ph.D. serves as Independent Director of the Company. Dr. Kumar has served as a director of OpCo, our wholly owned subsidiary, since June 2019. He co-founded Onconova Therapeutics, Inc. in 1998 and served as its Chief Executive Officer and a member of its board from 1998 to February 2019 and as its President from 1998 to June 2018. Dr. Kumar transitioned to an Advisory role with Onconova in January 2019. He has held positions in R&D and management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he served as President of the Genomics and Transgenics Division. Dr. Kumar obtained an undergraduate and Master’s degree in Microbiology from Panjab University and received his Ph.D. in Molecular Biology from the University of Illinois, Chicago and trained at the National Cancer Institute. Our Board believes Dr. Kumar’s extensive senior executive and public company experience, and familiarity with the pharmaceutical industry qualify him to serve on our Board.

What is Ramesh Kumar's net worth?: The estimated net worth of Ramesh Kumar is at least $5,775.00 as of July 19th, 2021. Dr. Kumar owns 7,500 shares of Ocugen stock worth more than $5,775 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Kumar may own. Learn More about Ramesh Kumar's net worth.
How do I contact Ramesh Kumar?: The corporate mailing address for Dr. Kumar and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Ramesh Kumar's contact information.
Has Ramesh Kumar been buying or selling shares of Ocugen?: Ramesh Kumar has not been actively trading shares of Ocugen during the last ninety days. Most recently, Ramesh Kumar sold 4,500 shares of the business's stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $1.83, for a transaction totalling $8,235.00. Learn More on Ramesh Kumar's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.
Are insiders buying or selling shares of Ocugen?: In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $9,100.00. The most recent insider tranaction occured on November, 26th when Director Prabhavathi Fernandes bought 10,000 shares worth more than $9,100.00. Insiders at Ocugen own 4.3% of the company. Learn More about insider trades at Ocugen.
Information on this page was last updated on 11/26/2024.

Ramesh Kumar Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2022	Sell	4,500	$1.83	$8,235.00
7/18/2022	Sell	7,500	$2.57	$19,275.00
4/18/2022	Sell	7,500	$2.83	$21,225.00
1/18/2022	Sell	7,500	$4.07	$30,525.00
7/19/2021	Sell	7,500	$6.40	$48,000.00	7,500
4/19/2021	Sell	7,500	$5.33	$39,975.00	7,500

Ramesh Kumar Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.77

$0.73

$0.80

50 Day Range

MA: $0.92

$0.75

$1.08

2 Week Range

Now: $0.77

$0.37

$2.11

Volume

21,568,055 shs

Average Volume

6,006,622 shs

Market Capitalization

$224.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.82